Oruka Therapeutics, Inc. (ORKA) — SEC Filings
Oruka Therapeutics, Inc. (ORKA) — 49 SEC filings. Latest: EFFECT (Apr 13, 2026). Includes 21 8-K, 7 SC 13G/A, 6 10-Q.
View Oruka Therapeutics, Inc. on SEC EDGAR
Overview
Oruka Therapeutics, Inc. (ORKA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 11, 2025: Oruka Therapeutics, Inc. filed an 8-K on December 11, 2025, reporting on the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements. The filing also includes financial statements and exhibits. Oruka Therapeutics, Inc.
Sentiment Summary
Across 49 filings, the sentiment breakdown is: 47 neutral, 2 mixed. The dominant filing sentiment for Oruka Therapeutics, Inc. is neutral.
Filing Type Overview
Oruka Therapeutics, Inc. (ORKA) has filed 1 EFFECT, 21 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 2 SC 13D/A, 1 S-1, 7 SC 13G/A, 5 SC 13G, 2 SC 13D with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (49)
Risk Profile
Risk Assessment: Of ORKA's 33 recent filings, 2 were flagged as high-risk, 22 as medium-risk, and 9 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | N/A |
| Net Income | -$75.850M |
| EPS | N/A |
| Debt-to-Equity | 0.05 |
| Cash Position | $91.253M |
| Operating Margin | N/A |
| Total Assets | $509.251M |
| Total Debt | $22.460M |
Key Executives
- Peter Harwin
- Tomas Kiselak
- Paul Quinlan
- Robert Atchinson
- David Epstein
- David J. Earp
- Dr. Michael J. Yaszemski
- Michael J. Yaszemski
Industry Context
Oruka Therapeutics operates in the highly competitive and capital-intensive biotechnology sector, focusing on drug development. The industry is characterized by long development cycles, high failure rates, and significant regulatory hurdles. Success often depends on substantial R&D investment, strategic partnerships, and successful capital raises to fund clinical trials and commercialization.
Top Tags
corporate-governance (9) · material-agreement (5) · filing (4) · 10-Q (4) · director-changes (3) · equity-sale (3) · definitive-agreement (3) · ownership-change (3) · biotech (3) · officer-changes (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss (9 months) | $75.850M | Increased from $57.943M in prior year period, indicating widening losses. |
| Cash and Cash Equivalents | $91.253M | Increased from $61.575M at Dec 31, 2024, providing liquidity. |
| 2025 PIPE Financing Proceeds | $180.000M | Significant capital raise to fund operations and R&D. |
| Research and Development (9 months) | $73.000M | Increased from $49.557M, reflecting intensified drug development. |
| Accumulated Deficit | $159.574M | Grew from $83.724M, highlighting continued unprofitability. |
| Common Stock Outstanding | 48,409,232 | As of October 31, 2025, indicating potential dilution from financing activities. |
| Net Cash Used in Operating Activities (9 months) | $65.616M | Increased from $39.019M, showing higher cash burn. |
| Total Assets | $509.251M | Increased from $396.019M, primarily due to cash from financing. |
| Revenue | $0 | Reported for the quarter ended June 30, 2025, indicating a pre-commercial stage. |
| Par value per share | 0.001 | Common stock par value, a nominal accounting value. |
| Months | 12 | Period for which Oruka Therapeutics, Inc. confirmed filing all required reports. |
| Days | 90 | Period for which Oruka Therapeutics, Inc. confirmed being subject to filing requirements. |
| Quarter end date | 2025-06-30 | The period covered by this 10-Q filing. |
| Filing date | 2025-08-11 | Date the 10-Q was filed with the SEC. |
| Business Phone | 650-606-7910 | Contact number for Oruka Therapeutics, Inc. |
Frequently Asked Questions
What are the latest SEC filings for Oruka Therapeutics, Inc. (ORKA)?
Oruka Therapeutics, Inc. has 49 recent SEC filings from Jan 2024 to Apr 2026, including 21 8-K, 7 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of ORKA filings?
Across 49 filings, the sentiment breakdown is: 47 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Oruka Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Oruka Therapeutics, Inc. (ORKA) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Oruka Therapeutics, Inc.?
Key financial highlights from Oruka Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for ORKA?
The investment thesis for ORKA includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Oruka Therapeutics, Inc.?
Key executives identified across Oruka Therapeutics, Inc.'s filings include Peter Harwin, Tomas Kiselak, Paul Quinlan, Robert Atchinson, David Epstein and 3 others.
What are the main risk factors for Oruka Therapeutics, Inc. stock?
Of ORKA's 33 assessed filings, 2 were flagged high-risk, 22 medium-risk, and 9 low-risk.
What are recent predictions and forward guidance from Oruka Therapeutics, Inc.?
Forward guidance and predictions for Oruka Therapeutics, Inc. are extracted from SEC filings as they are enriched.